Sucrose octasulfate sodium
Based on 1 Customer Validation
Sucrose octasulfate sodium, a derivative of sulfated oligosaccharides, is a matrix metalloproteinase (MMP) inhibitor. Sucrose octasulfate sodium stimulates the release of somatostatin-like immunoreactivity (SLI) from the stomach by acting directly on D cells in the gastric mucosa. Sucrose octasulfate sodium exerts its ulcer-healing effect by releasing endogenous gastric somatostatin. Sucrose octasulfate sodium can be used as a pharmaceutical excipient and significantly improves wound closure in diabetic foot ulcers caused by nerve ischemia and venous leg ulcers. Sucrose octasulfate sodium can be used in the study of chronic wound healing.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 74135-10-7
- Formula: C12H14Na8O35S8
- Molecular Weight:1158.66
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Neuronal Signaling Compound Library
HY-L013
-
Differentiation Inducing Compound Library
HY-L038
-
Anti-diabetic Compound Library
HY-L040
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Pain-Related Compound Library
HY-L139
-
Protease Inhibitor Library
HY-L147
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Multi-Target Compound Library
HY-L176
-
Anti-Fibrosis Compound Library
HY-L185
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Biological Activity
Sucrose octasulfate (2.5-20 mg/mL; 2 h) sodium dose-dependently stimulates somatostatin-like immunoreactivity release from isolated canine gastric fundic D-cells, potentiating epinephrine-induced release at 10 and 20 mg/mL but only adding to gastrin heptadecapeptide-induced release[3].
Sucrose octasulfate (2.5-20 mg/mL; 2 h) sodium potentiates dibutyryl cyclic adenosine 3',5'-monophosphate-induced somatostatin-like immunoreactivity release from isolated canine gastric fundic D-cells, but does not potentiate 12-O-tetradecanoylphorbol 13-acetate-induced release[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 74135-10-7
-
Appearance Solid
-
Molecular Weight 1158.66
-
Formula C12H14Na8O35S8
-
Color White to light yellow
-
SMILES
O=[S](OC[C@]([C@H]([C@@H]1O[S](=O)(O[Na])=O)O[S](=O)(O[Na])=O)(O[C@@H]1CO[S](=O)(O[Na])=O)O[C@@H](O[C@@H]2CO[S](=O)(O[Na])=O)[C@@H]([C@H]([C@@H]2O[S](=O)(O[Na])=O)O[S](=O)(O[Na])=O)O[S](=O)(O[Na])=O)(O[Na])=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H2O : 116.67 mg/mL (100.69 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (289 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Edmonds M, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018;6(3):186-196. [Content Brief]
[2]. Lucey MR, et al. Sucrose octasulfate stimulates gastric somatostatin release. Am J Med. 1991;91(2A):52S-57S. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.8631 mL | 4.3153 mL | 8.6307 mL | 21.5766 mL |
| 5 mM | 0.1726 mL | 0.8631 mL | 1.7261 mL | 4.3153 mL | |
| 10 mM | 0.0863 mL | 0.4315 mL | 0.8631 mL | 2.1577 mL | |
| 15 mM | 0.0575 mL | 0.2877 mL | 0.5754 mL | 1.4384 mL | |
| 20 mM | 0.0432 mL | 0.2158 mL | 0.4315 mL | 1.0788 mL | |
| 25 mM | 0.0345 mL | 0.1726 mL | 0.3452 mL | 0.8631 mL | |
| 30 mM | 0.0288 mL | 0.1438 mL | 0.2877 mL | 0.7192 mL | |
| 40 mM | 0.0216 mL | 0.1079 mL | 0.2158 mL | 0.5394 mL | |
| 50 mM | 0.0173 mL | 0.0863 mL | 0.1726 mL | 0.4315 mL | |
| 60 mM | 0.0144 mL | 0.0719 mL | 0.1438 mL | 0.3596 mL | |
| 80 mM | 0.0108 mL | 0.0539 mL | 0.1079 mL | 0.2697 mL | |
| 100 mM | 0.0086 mL | 0.0432 mL | 0.0863 mL | 0.2158 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Sucrose octasulfate sodium Related Classifications
HY-137273 Related Classifications
Powered by Bioz
- Sucrose octasulfate
- 74135-10-7
- Somatostatin Receptor
- MMP
- canine fundic D-cells
- perfused rat stomach
- somatostatin-like immunoreactivity
- matrix metalloproteinase
- epinephrine
- dibutyryl cyclic adenosine 3',5'-monophosphate
- growth factors
- canine parietal cell
- extracellular matrix components
- neuroischaemic diabetic foot ulcers
- Inhibitor
- inhibitor
- inhibit